2.07
+5.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genelux
From its filings with the US Securities and Exchange Commission
Genelux is based in Westlake Village, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GNLX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $8,000 and a net loss of $32.1m. At that date it held total assets of $19.0m and shareholders' equity of $11.5m.
Phase 1b/2 clinical trial in China to treat patients with recurrent small cell lung cancer (SCLC).
Newsoara HYK Biopharmaceuticals Co., Ltd. We refer herein to the counterparty to the Newsoara License Agreement as Newsoara.
Kong and Macau (the Newsoara Territory) in the field of human diagnostic, prophylactic and therapeutic uses (the Newsoara Field).
Astrazeneca, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Johnson & Johnson, Eli Lilly & Co., and Bristol Myers Squibb.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jan 2023
- Employees
- 25
- Website
- genelux.com ↗
- Head office
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Thomas ZindrickChairman of the Board, President, Chief Executive Officer, since 2014$1.5m
- Mr. Matthew PulisicChief Financial Officer
- Dr. Tony YuSenior Vice President - Clinical Development
- Dr. Joseph CappelloChief Technical Officer$601,814
- Mr. Eric GroenGeneral Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
- Dr. Paul ScigallaChief Medical Officer
- Mr. Ralph SmallingHead - Regulatory
- Mr. James TyreeLead Independent Director$225,000
- Ms. Mary MirabelliIndependent Director$215,500
- Mr. John SmitherIndependent Director$231,500
- Dr. John ThomasIndependent Director$219,000
- Dr. Ankit BhargavaIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 56
- Social
- 85
- Governance
- 26
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genelux Corp focuses on oncolytic viral immunotherapies for solid tumors with Olvi-Vec in Phase II trials.
- The company develops V2ACT Immunotherapy for personalized anti-cancer therapy targeting neoantigen-specific T cells.
- Genelux Corp's V-VET1 is a veterinary-grade oncolytic vaccinia virus for animal health applications.
Weaknesses
- Genelux Corp has only 15 full-time employees in Westlake Village, California.
- The company's IPO occurred on 26 January 2023 with limited market presence.
- Genelux Corp's business is concentrated on a single Phase II clinical trial for Olvi-Vec.
Opportunities
- Genelux Corp can expand its V2ACT Immunotherapy to additional cancer types beyond ovarian cancer.
- The company may leverage V-VET1 for broader animal health market opportunities.
- Genelux Corp could seek partnerships for clinical trials in platinum resistant/refractory ovarian cancer.
Threats
- Genelux Corp faces competition from other biotechnology firms in oncolytic viral therapies.
- The Phase II trial for Olvi-Vec could encounter delays or failure in clinical outcomes.
- Regulatory approval for Olvi-Vec and V2ACT may require significant additional funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.